(redirected from hematopoietic growth factor)
Also found in: Dictionary, Thesaurus, Medical, Financial, Encyclopedia.


An event, circumstance, influence, or element that plays a part in bringing about a result.

A factor in a case contributes to its causation or outcome. In the area of Negligence law, the factors, or chain of causation, are important in determining whether liability ensues from a particular action done by the defendant.

West's Encyclopedia of American Law, edition 2. Copyright 2008 The Gale Group, Inc. All rights reserved.


n. 1) a salesman who sells in his/her own name on behalf of others, taking a commission for services. 2) something that contributes to the result.

Copyright © 1981-2005 by Gerald N. Hill and Kathleen T. Hill. All Right reserved.


1 a mercantile agent. An agent who is in the ordinary course of business entrusted with goods or documents of title representing goods with a view to their sale. A factor has a lien over goods entrusted to him; this lien covers any claims he may have against his principal arising out of the agency. Most factors will be mercantile agents (and have the powers of such) for the purposes of the Factors Act 1889. Under this Act, in certain circumstances a factor may pass a good title to goods entrusted to him.
2 an institution to whom a company assigns its book debts (see FACTORING).
3 in Scotland a landlord or superior's agent.
Collins Dictionary of Law © W.J. Stewart, 2006
References in periodicals archive ?
In addition to the activation by hematopoietic growth factors, p38 MAPK can be activated by cytokines that negatively regulate normal hematopoiesis, which include type I interferons (IFNs) (IFN-[alpha], IFN-[beta]).
Some chapters are broader in scope, discussing such topics as clinical strategies for cancer treatment, preclinical aspects of cancer drug discovery, pharmacokinetics, infertility after cancer chemotherapy, carcinogenesis of anticancer drugs, antibody therapies of cancer, hematopoietic growth factors, the role of the Food and Drug Administration in oncology product development, and hormonal therapy for breast cancer.
Hematopoietic growth factors and monoclonal antibodies, increasingly advocated as adjunctive agents to prolong the duration of treatment and reduce tumor growth, added still more costs.
Pecora concluded, "Expanded stem cells have the potential to provide a therapeutic benefit similar to hematopoietic growth factors; improving bone marrow function resulting in fewer infections, less bleeding complications and better overall outcomes."
At the same time, the advent of hematopoietic growth factors and the use of peripheral stem cell transplants has lowered the risk of the procedure.

Full browser ?